Pramipexole 2HCl Monohydrate - 10mM in DMSO , D2-like dopamine receptor agonist, CAS No.191217-81-9, D2-like dopamine receptor agonist

CAS: 191217-81-9 Cat. No.: P408146 Formula: C₁₀H₁₇N₃S·2HCl·H₂O Peso molecolare: 302.26 Numero EC: 687-708-9 PubChem CID: 166589

GRADE & PURITY 10mM in DMSO

Synonyms

(6S)​- 4,​5,​6,​7-​tetrahydro-​N6-​propyl-2,​6-​benzothiazolediamine,hydrochloride,hydrate (1:2:1)

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Panoramica

Information

Pramipexole 2HCl Monohydrateis a novel non-ergoline dopamine (DA) agonist, used to treat Parkinson's disease.
In vitro

Pramipexole, a chemically novel dopamine agonist used for the treatment of Parkinson\'s disease symptoms, possesses antioxidant activity and is neuroprotective toward substantia nigral dopamine neurons in hypoxic-ischemic and methamphetamine models. Pramipexole reduces the levels of oxygen radicals produced by methylpyridinium ion (MPP+) both when incubated with SH-SY5Y cells and when perfused into rat striatum. Pramipexole also exhibits a concentration-dependent inhibition of opening of the mitochondrial transition pore induced by calcium and phosphate or MPP+. Pramipexole decreases the levels of dopamine metabolites dose dependently, whereas striatal dopamine levels remains unchanged. Pramipexole acts in both of these models to reduce the elevated dopamine turnover and the associated elevation in hydroxyl radical production secondary to increased MAO activity that could be responsible for oxidative damage to the nigrostriatal neurons. Pramipexole (4-100 mM) significantly attenuates DA- or L-DOPA-induced cytotoxicity and apoptosis, an action which is not blocked by D3 antagonist U-99194 A or D2 antagonist raclopride. Pramipexole also protects MES 23.5 cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. Pramipexole can effectively inhibit the formation of melanin, an end product resulting from DA or L-DOPA oxidation in cell-free system.

In vivo

Pramipexole (0.001-1 mg/kg s.c.) reduces exploratory locomotor activity in mice. Pramipexole (1 mg/kg, p.o.) is able to significantly reduce the increased DA turnover, but by only 16%.
Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Sinonimi

(6S)​- 4,​5,​6,​7-​tetrahydro-​N6-​propyl-2,​6-​benzothiazolediamine,hydrochloride,hydrate (1:2:1)

Specifiche e purezza

10mM in DMSO

Meccanismi biochimici e fisiologici

Pramipexole 2HCl Monohydrateis a novel non-ergoline dopamine (DA) agonist, used to treat Parkinson\'s disease.

Condizioni di conservazione di stoccaggio

Store at -80°C

Spedito in

Dry ice packs + Cold packs

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Tipo di azione

AGONIST

Meccanismo d'azione

D2-like dopamine receptor agonist

Nomi e identificatori

Isomeri SMILES

CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl

CAS alternativo

191217-81-9

PubChem CID

166589

Termini MeSH

2 Amino 6 propylaminotetrahydrobenzothiazole;2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole;2-amino-6-propylaminotetrahydrobenzothiazole;4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine;6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydr

Peso molecolare

302.26

Proprietà chimiche e fisiche

• Solubilità: Solubility (25°C) In vitro DMSO: 35 mg/mL (202.06 mM); Water: Insoluble; Ethanol: 35 mg/mL
• Rotazione specifica [α]: -67° (C=1,MeOH)
• Punto di fusione (°C): 296-305°C